Analysts forecast that Cellectis SA (NASDAQ:CLLS) will announce ($0.64) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Cellectis’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.69). Cellectis posted earnings of $0.02 per share in the same quarter last year, which would indicate a negative year over year growth rate of 3,300%. The firm is scheduled to announce its next earnings report on Monday, March 5th.
On average, analysts expect that Cellectis will report full year earnings of ($2.89) per share for the current year, with EPS estimates ranging from ($3.11) to ($2.67). For the next year, analysts forecast that the business will post earnings of ($2.62) per share, with EPS estimates ranging from ($2.88) to ($2.29). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Cellectis.
Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, November 13th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.16). Cellectis had a negative return on equity of 30.66% and a negative net margin of 217.25%.
CLLS has been the subject of a number of recent research reports. Oppenheimer restated an “outperform” rating and issued a $40.00 price objective on shares of Cellectis in a report on Thursday, December 28th. Jefferies Group restated a “buy” rating and issued a $47.00 price objective on shares of Cellectis in a report on Tuesday, September 26th. SunTrust Banks restated a “hold” rating and issued a $20.00 price objective on shares of Cellectis in a report on Friday, October 6th. BidaskClub raised shares of Cellectis from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 4th. Finally, Zacks Investment Research downgraded shares of Cellectis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Cellectis presently has a consensus rating of “Buy” and an average target price of $39.29.
Hedge funds and other institutional investors have recently modified their holdings of the stock. ARK Investment Management LLC increased its stake in shares of Cellectis by 79.1% in the second quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after buying an additional 1,784 shares during the period. Williams Jones & Associates LLC purchased a new position in shares of Cellectis in the second quarter worth $244,000. Wells Fargo & Company MN increased its stake in shares of Cellectis by 132.1% in the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after buying an additional 5,435 shares during the period. KBC Group NV purchased a new position in shares of Cellectis in the third quarter worth $366,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Cellectis in the third quarter worth $517,000. 16.35% of the stock is currently owned by institutional investors.
Shares of Cellectis (CLLS) traded up $3.01 on Friday, hitting $32.49. 873,966 shares of the stock were exchanged, compared to its average volume of 201,422. The company has a market cap of $1,170.00 and a price-to-earnings ratio of -11.73. Cellectis has a 1 year low of $17.29 and a 1 year high of $35.07.
WARNING: This story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/14/cellectis-sa-clls-expected-to-post-earnings-of-0-64-per-share.html.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Get a free copy of the Zacks research report on Cellectis (CLLS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.